Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adrenocorticotropic hormone + prednisone
- Development stage
- Unknown
- Lead developer
- Mao Jianhua
- Modality
- Peptides, Small Molecules
- Administration
- Intramuscular, Subcutaneous, Oral
01
Overview
adrenocorticotropic hormone + prednisone is a combination therapy being evaluated in a Phase 3 clinical trial led by Mao Jianhua for the treatment of children with frequently relapsing or steroid-dependent nephrotic syndrome. Adrenocorticotropic hormone (ACTH) is a peptide hormone that acts as an agonist at melanocortin receptors. Its therapeutic effect in nephrotic syndrome is twofold: it stimulates the adrenal cortex to produce endogenous cortisol via the melanocortin 2 receptor (MC2R) and exerts direct reno-protective effects on glomerular podocytes through the melanocortin 1 receptor (MC1R). Prednisone, a synthetic glucocorticoid, complements this by providing potent systemic anti-inflammatory and immunosuppressive activity through the glucocorticoid receptor. This combination approach aims to achieve and maintain remission in pediatric patients who have failed or become dependent on standard steroid tapering protocols.
- Other names
- ACTH + prednisonecorticotropin + prednisoneadrenocorticotrophic hormone + prednisone
02
Targets
GR (Glucocorticoid receptor)MC2R (Adrenocorticotropic Hormone Receptor)
Beyond the preview
Go deeper on adrenocorticotropic hormone + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adrenocorticotropic hormone + prednisone.